We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Ardelyx, Inc. is next on our list.
TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating. The adjustment followed an update to the firm’s financial model ahead of the ARDX’s fourth-quarter results.
Additionally, on January 27, Jefferies also raised its price target on Ardelyx, Inc. (NASDAQ:ARDX) to $15 from $8 and maintained a Buy rating. The firm highlighted the company as one of the most underrated biotech launches and underlined sustained execution on Ibsrela in 2026, along with potential upside from IBS-C, new CIC indications, and extended intellectual property. Peak sales are now projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable.
Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing first‑in‑class gastrointestinal and cardiorenal therapies. Its lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS‑C) and chronic kidney disease‑related conditions.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
